Epidemiology and Outcomes of Invasive Candidiasis Due to Non-albicans Species of Candida in 2,496 Patients: Data from the Prospective Antifungal Therapy (PATH) Registry 2004–2008
Open accessThe DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.
Abstract
This analysis describes the epidemiology and outcomes of invasive candidiasis caused by non-albicans species of Candida in patients enrolled in the Prospective Antifungal Therapy Alliance (PATH Alliance) registry from 2004 to 2008. A total of 2,496 patients with non-albicans species of Candida isolates were identified. The identified species were C. glabrata (46.4%), C. parapsilosis (24.7%), C. tropicalis (13.9%), C. krusei (5.5%), C. lusitaniae (1.6%), C. dubliniensis (1.5%) and C. guilliermondii (0.4%); 111 infections involved two or more species of Candida (4.4%). Non-albicans species accounted for more than 50% of all cases of invasive candidiasis in 15 of the 24 sites (62.5%) that contributed more than one case to the survey. Among solid organ transplant recipients, patients with non-transplant surgery, and patients with solid tumors, the most prevalent non-albicans species was C. glabrata at 63.7%, 48.0%, and 53.8%, respectively. In 1,883 patients receiving antifungal therapy on day 3, fluconazole (30.5%) and echinocandins (47.5%) were the most frequently administered monotherapies. Among the 15 reported species, 90-day survival was highest for patients infected with either C. parapsilosis (70.7%) or C. lusitaniae (74.5%) and lowest for patients infected with an unknown species (46.7%) or two or more species (53.2%). In conclusion, this study expands the current knowledge of the epidemiology and outcomes of invasive candidiasis caused by non-albicans species of Candida in North America. The variability in species distribution in these centers underscores the importance of local epidemiology in guiding the selection of antifungal therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“although C. glabrata has been reported to represent more than 30% of the non-albicans Candida in some geographic areas [4, 6–9].”
From Invasive candidiasis species distribution and trends, United States, 2009-2017 (2021) · cites this paper as [7]
In the citing paper
“C. glabrata bloodstream infections are commonly found in elderly individuals, diabetic patients and solid organ transplant recipients [6,8,9].”
From Candida glabrata: A Lot More Than Meets the Eye (2019) · cites this paper as [8]
In the citing paper
“The emergence of resistant strains, including those becoming resistant to multiple drugs, has been increasingly reported in recent years [14,15,16].”
From Evolutionary Emergence of Drug Resistance in Candida Opportunistic Pathogens (2018) · cites this paper as [14]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem
Pfaller, M. A., & Diekema, D. J. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00029-06 · Cited by 4,174 · cited 1×
“More than 30 species of Candida have been reported to cause IC [3–6].”
BackgroundSelf-citationPappas, P. G., Kauffman, C. A., Andes, D., Benjamin, D. K., Calandra, T. F., Edwards, J. E., Filler, S. G., Fisher, J. F., Kullberg, B.-J., Zeichner, L. O., et al. (2009) · Clinical Infectious Diseases · doi:10.1086/596757 · Cited by 3,191 · cited 2×
“parapsilosis, the early removal of central venous catheters remains an important principle in the management of candidemia caused by this species [29].”
BackgroundSelf-citationAscioglu, S., Rex, J. H., de Pauw, B., Bennett, J. E., Bille, J., Crokaert, F., Denning, D. W., Donnelly, J. P., Edwards, J. E., Erjavec, Z., et al. (2002) · Clinical Infectious Diseases · doi:10.1086/323335 · Cited by 2,331 · cited 1×
“from blood cultures and other forms of IC (proven or probable) were defined according to the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group criteria [33].”
MethodCornely, O. A., Bassetti, M., Calandra, T., Garbino, J., Kullberg, B. J., Lortholary, O., Meersseman, W., Akova, M., Arendrup, M. C., Arikan-Akdagli, S., et al. (2012) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12039 · Cited by 1,217 · cited 4×
“On reviewing the approaches to antifungal therapy reported by the participating centers, several appear to be at odds with current consensus guidelines [28–30] and reported susceptibility profiles in the literature [14,21].”
BackgroundResultInfluentialEpidemiology of Invasive Mycoses in North America
Pfaller, M. A., & Diekema, D. J. (2010) · Critical Reviews in Microbiology · doi:10.3109/10408410903241444 · Cited by 901 · cited 2×
“7%, in keeping with other reports [1].”
BackgroundSelf-citationAndes, D. R., Safdar, N., Baddley, J. W., Playford, G., Reboli, A. C., Rex, J. H., Sobel, J. D., Pappas, P. G., Kullberg, B. J., & for the Mycoses Study Group (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis021 · Cited by 793 · cited 2×
“Indeed Andes et al [39] found in a patient-level T a b le 1 .”
BackgroundSelf-citationAlexander, B. D., Johnson, M. D., Pfeiffer, C. D., Jiménez-Ortigosa, C., Catania, J., Booker, R., Castanheira, M., Messer, S. A., Perlin, D. S., & Pfaller, M. A. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cit136 · Cited by 778 · cited 2×
“glabrata with co-resistance to both azoles and echinocandins in some medical centers [12,13,20].”
BackgroundSelf-citationThe changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance
Hong Nguyen, M., Peacock, J. E., Morris, A. J., Tanner, D. C., Nguyen, M. L., Snydman, D. R., Wagener, M. M., Rinaldi, M. G., & Yu, V. L. (1996) · The American Journal of Medicine · doi:10.1016/s0002-9343(95)00010-0 · Cited by 758 · cited 2×
“glabrata has been reported by other investigators [23–27]; however, a recent systematic review by Falagas et al.”
BackgroundResultPfaller, M. A., Diekema, D. J., Gibbs, D. L., Newell, V. A., Ellis, D., Tullio, V., Rodloff, A., Fu, W., & Ling, T. A. (2010) · Journal of Clinical Microbiology · doi:10.1128/jcm.02117-09 · Cited by 718 · cited 1×
“While some of these species have been designated as ‘emerging’ species, the apparent increased detection of these species may simply reflect the more vigorous efforts to identify clinical isolates of Candida to the species level in recent years [6,20,46].”
BackgroundSelf-citationPfaller, M. A., & Diekema, D. J. (2004) · Journal of Clinical Microbiology · doi:10.1128/jcm.42.10.4419-4431.2004 · Cited by 694 · cited 3×
“4% of all N-CA isolates in this registry, there are several that merit attention either because they have been shown to cause clusters of infection in the hospital setting, because they are frequently misidentified by conventional methods or represent ‘cryptic’ species, or because they exhibit decreased susceptibility…”
BackgroundSelf-citation
Research works printed but not linked: 1
- 31. Horn D, Neofytos D (2007) Contemporary patterns in the use of antifungal agents in the treatment of invasive fungal infections: perspectives from registries and databases. Curr Fungal Infect Rep 1: 72-78.
Cited by
Items 201–300 of 406
Cretella, D. A., Barber, K. E., King, S. T., & Stover, K. R. (2016) · Journal of Medical Microbiology · doi:10.1099/jmm.0.000383 · Cited by 16
“Candida albicans has been the most commonly encountered species historically, but recent data reveal a growing prevalence of non-albicans Candida, notably Candida glabrata, Candida krusei, Candida parapsilosis and Candida tropicalis, as the cause of invasive infection (Tortorano et al., 2013; Bustamante et al., 2014;…”
BackgroundBarbosa, A. H., Damasceno, J. L., Casemiro, L. A., Martins, C. H. G., Pires, R. H., & Cândido, R. C. (2019) · Journal of Prosthodontics · doi:10.1111/jopr.13037 · Cited by 17
Mixed fungaemia: an 18-year report from a tertiary-care university hospital and a systematic review
Gülmez, D., Alp, Ş., Gürsoy, G., Ayaz, Ç. M., Doğan, Ö., Arıkan-Akdağlı, S., & Akova, M. (2020) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2020.03.030 · Cited by 16
Alvarez-Rueda, N., Rouges, C., Touahri, A., Misme‐Aucouturier, B., Albassier, M., & Pape, P. L. (2020) · Scientific Reports · doi:10.1038/s41598-020-63344-6 · Cited by 17
Aşkun, T. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.100869 · Cited by 16
Amanati, A., Badiee, P., Jafarian, H., Ghasemi, F. S., Nematolahi, S., Haghpanah, S., & Hamzavi, S. S. (2021) · Scientific Reports · doi:10.1038/s41598-021-93421-3 · Cited by 14
Fernández-Pereira, J., Alvarado, M. I., Gómez-Molero, E., Dekker, H. L., Muñoz, M. T. B., Eraso, E., Bader, O., & de Groot, P. W. J. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.790465 · Cited by 16
Ollinger, T. L., Vu, B. G., Murante, D., Parker, J. E., Šimoničová, L., Doorley, L. A., Stamnes, M. A., Kelly, S. L., Rogers, P. D., Moye-Rowley, S., et al. (2021) · mSphere · doi:10.1128/msphere.00830-21 · Cited by 14
“glabrata is the second most common cause of candidiasis in most clinical case series of invasive infections (1, 2).”
BackgroundEvolution and Application of Inteins in Candida species: A Review
Fernandes, J. A. L., Prandini, T. H. R., Castro, M. D. C. A., Arantes, T. D., Giacobino, J., Bagagli, E., & Theodoro, R. C. (2016) · Frontiers in Microbiology · doi:10.3389/fmicb.2016.01585 · Cited by 16
“(Pfaller et al., 2014).”
Defosse, T. A., Govic, Y. L., Courdavault, V., Clastre, M., Vandeputte, P., Chabasse, D., Bouchara, J.-P., Giglioli‐Guivarc’h, N., & Papon, N. (2018) · Journal de Mycologie Médicale · doi:10.1016/j.mycmed.2018.02.009 · Cited by 15
“[28] Pfaller MA, Andes DR, Diekema DJ, Horn DL, Reboli AC, Rotstein C, et al.”
BackgroundCandidemia in Children Caused by Uncommon Species of Candida
Charsizadeh, A., Mirhendi, H., Nikmanesh, B., Eshaghi, H., Rahmani, M., Farhang, A., Bakhshi, H., & Makimura, K. (2018) · Archives of Pediatric Infectious Diseases · doi:10.5812/pedinfect.11895 · Cited by 14
Boan, P., & Gardam, D. J. (2019) · Journal of Chemotherapy · doi:10.1080/1120009x.2019.1595895 · Cited by 17
Risk prediction for candidemia in surgical intensive care unit patients
Ulu-Kılıç, A., Basaga, S. M., Cevahir, F., Çakır, Ö. Ö., Doğanay, M., & Alp, E. (2020) · Northern Clinics of Istanbul · doi:10.14744/nci.2020.27136 · Cited by 18
“In addition, mortality attributed to candidemia is high as 47% among adults and 29% among children [3].”
BackgroundBrouwer, C. P. J. M., van der Linden, Y., Carrasco, M. R., Alwasel, S. H., Abalkhail, T., Al-Otibi, F. O., Boekhout, T., & Welling, M. M. (2025) · Antibiotics · doi:10.3390/antibiotics14070671 · Cited by 13
Candida krusei form mycelia along agar surfaces towards each other and other Candida species
Fleischmann, J., Broeckling, C. D., & Lyons, S. M. (2017) · BMC Microbiology · doi:10.1186/s12866-017-0972-z · Cited by 15
“Candida krusei while representing a small percentage of these isolates, has become important as a pathogen for immunocompromised patients, especially because of its intrinsic resistance to some anti-fungal agents [17].”
Shiradhone, A. B., Ingle, S., & Zore, G. B. (2018) · Journal of Fungi · doi:10.3390/jof4020047 · Cited by 13
“Candida species are the fourth most common cause of nosocomial bloodstream infection, with a crude mortality rate of 50%, the highest amongst nosocomial bloodstream infections [4,5].”
BackgroundHoffmann, D. E., Diderrich, R., Reithofer, V., Friederichs, S., Kock, M. A., Essen, L., & Mösch, H. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ra120.013968 · Cited by 15
“pET-28(a)1 PT7 63His lacI Kan R Merck, Germany BHUM1829 Epa1A EPA1((31-271)) in pET-28(a)1 15 BHUM1784 Epa2A EPA2((32-262)) in pET-28(a)1 15 BHUM1788 Epa3A EPA3((28-264)) in pET-28(a)1 15 BHUM1790 Epa6A EPA6((26-271)) in pET-28(a)1 15 BHUM1886 Epa9A EPA9((39-305)) in pET-28(a)1 15 BHUM2495 Epa10A EPA10((39-306)) in pE…”
BackgroundArtemisinin Targets Transcription Factor PDR1 and Impairs Candida glabrata Mitochondrial Function
Zhu, P., Yue, C., Zeng, X., & Chen, X. (2022) · Antioxidants · doi:10.3390/antiox11101855 · Cited by 18
Wang, Y., Xu, J., Abid, F. B., Salah, H., Sundararaju, S., Ismail, K. A., Wang, K., Matthew, L. S., Taj‐Aldeen, S. J., Ibrahim, E. B., et al. (2024) · Microbial Genomics · doi:10.1099/mgen.0.001179 · Cited by 15
Nanosized devices as antibiotics and antifungals delivery: past, news, and outlook
Furneri, P. M., Petronio, G. P., Fuochi, V., Cupri, S., & Pignatello, R. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-46143-6.00023-3 · Cited by 20
The Role of In Vitro Susceptibility Testing in the Management of Candida and Aspergillus
Ostrosky-Zeichner, L. L., & Andes, D. R. (2017) · The Journal of Infectious Diseases · doi:10.1093/infdis/jix239 · Cited by 14
Self-citationJain, K., Wadhwa, K., MALIK, M. L., Haque, S., Prieto, M. A., & Kaur, H. (2025) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofaf742 · Cited by 13
Apoptosis of Multi‐Drug Resistant Candida Species on Microstructured Titanium Surfaces
Le, P. H., Linklater, D. P., Aburto‐Medina, A., Nie, S., Williamson, N. A., Crawford, R. J., MacLaughlin, S. A., & Ivanova, E. P. (2023) · Advanced Materials Interfaces · doi:10.1002/admi.202300314 · Cited by 14
Izadi, A., Paknia, F., Roostaee, M., Mousavi, S. A. A., & Barani, M. (2024) · Nanotechnology · doi:10.1088/1361-6528/ad4bed · Cited by 13
“Infections can be systemic (e.g. myocarditis, septicemia) or superficial (e.g. vaginal, mucocutaneous, or oral) [57, 60].”
BackgroundInfluentialCandida lusitaniae MICs to the echinocandins are elevated but FKS -mediated resistance is rare
Lockhart, S. R., Pham, C. D., Kuykendall, R. J., Bolden, C. B., & Cleveland, A. A. (2015) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2015.08.012 · Cited by 12
Carlesse, F. A. D. M. C., Cappellano, P., Quiles, M. G., Menezes, L. C., Petrilli, A. S., & Pignatari, A. C. C. (2016) · BMC Infectious Diseases · doi:10.1186/s12879-016-1792-8 · Cited by 12
“This is an uncommon species of Candida in these patients and it is important to note that it can be resistant to amphotericin B [28].”
BackgroundAntifungal pharmacodynamics: Latin America's perspective
González, J. M., Rodríguez, C. A., Agudelo, M., Zuluaga, A. F., & Vesga, Ó. (2016) · The Brazilian Journal of Infectious Diseases · doi:10.1016/j.bjid.2016.09.009 · Cited by 14
A copper(II)-binding triazole derivative with ionophore properties is active against Candida spp.
Gaspar‐Cordeiro, A., da Silva, S. M., Aguiar, M. M., Rodrigues‐Pousada, C., Haas, H., Lima, L. M. P., & Pimentel, C. (2020) · JBIC Journal of Biological Inorganic Chemistry · doi:10.1007/s00775-020-01828-6 · Cited by 16
Owoicho, O., Olwal, C. O., Tettevi, E. J., Atu, B. O., & Durugbo, E. U. (2022) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2022.2109963 · Cited by 12
“Moreover, some Candida species are intrinsically resistant or have reduced susceptibility to fluconazole, a widely used antifungal azole drug [2,9,10].”
BackgroundSpecial Issue: Candida and Candidiasis
Nett, J. E. (2018) · Journal of Fungi · doi:10.3390/jof4030074 · Cited by 12
“With immunosuppression, Candida becomes an invasive pathogen, leading to disseminated disease with mortality approaching 40% [1,2].”
Klonska raznolikost i antifungalna osjetljivost vrste Candida spp. izolirane iz mlijeka
Hızlısoy, H., Onmaz, N. E., Al, S., Karadal, F., Yıldırım, Y., Gönülalan, Z., GÜMÜŞSOY, K. S., Aydemir, G., Tekinsen, F. F., & Dinç, G. (2020) · Mljekarstvo/Mljekarstvo.com · doi:10.15567/mljekarstvo.2020.0104 · Cited by 11
Memon, S., Farooqi, J. Q., Zafar, U., Naqvi, S. F., Zafar, A., & Jabeen, K. (2021) · Journal of Medical Microbiology · doi:10.1099/jmm.0.001459 · Cited by 14
Experimental evolution of drug resistance in human fungal pathogens
Gerstein, A. C., & Sethi, P. (2022) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2022.101965 · Cited by 13
Multilocus microsatellite analysis of European and African Candida glabrata isolates
Chillemi, V., Passo, C. L., van Diepeningen, A. D., Rharmitt, S., Delfino, D., Cascio, A., Nnadi, N. E., Cılo, B. D., Sampaio, P., Tietz, H., et al. (2016) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-016-2610-3 · Cited by 11
Prevalence of Candida bloodstream isolates from patients in two hospitals in Vietnam
Bac, N. D., Le, T., Quang, L. B., Lực, N. K., Thi, T., Nagi, M., Yoshitsugu, M., Hà, H. T. T., Anh, Đ. Đ., Đỗ, Q., et al. (2019) · Iranian Journal of Microbiology · doi:10.18502/ijm.v11i2.1071 · Cited by 17
“The proportion of Candida species vary considerably among the patients with different risk factors as well as in different geographic areas (20).”
BackgroundWen, X., Chen, Q., Yin, H., Wu, S., & Wang, X. (2020) · Medicine · doi:10.1097/md.0000000000019194 · Cited by 32
“However, in recent years, the proportion of nonC albicans has increased rapidly.([30]) The antibacterial activity of antibacterial drugs varies with strains, and the choice of treatment drugs is also different([31]); early identification of the pathogenic species of IC is essential for early clinical medication.”
BackgroundKhan, Z., Ahmad, S., Al‐Sweih, N., Mokaddas, E. M., Al-Banwan, K., Alfouzan, W. A., Al‐Obaid, I., Alobaid, K., & Varghese, S. (2020) · Microbial Drug Resistance · doi:10.1089/mdr.2019.0437 · Cited by 13
Fraga‐Silva, T. F. D. C., Munhoz-Alves, N., Mimura, L. A. N., de Oliveira, L. R. C., Figueiredo-Godoi, L. M. A., Garcia, M. T., Oliveira, E. S., Ishikawa, L. L. W., Zorzella-Pezavento, S. F. G., Bonato, V. L. D., et al. (2022) · Journal of Fungi · doi:10.3390/jof8040386 · Cited by 11
“albicans is predominant, nonalbicans Candida species are also able to reach the CNS [6].”
BackgroundInvasive Fungal Infections and Approaches to Their Diagnosis
Pfaller, M. A. (2015) · Methods in microbiology · doi:10.1016/bs.mim.2015.05.002 · Cited by 13
Self-citationTaverna, C. G., Córdoba, S. B., Vivot, M. E., Szusz, W., Vivot, W., Bosco‐Borgeat, M. E., & Davel, G. (2018) · Medical Mycology · doi:10.1093/mmy/myy038 · Cited by 11
Leiva-Peláez, O., Gutiérrez-Escobedo, G., López-Fuentes, E., Cruz-Mora, J., De Las Peñas, A., & Castaño, I. (2018) · Fungal Genetics and Biology · doi:10.1016/j.fgb.2018.05.005 · Cited by 10
A Review of Studies on Candida Species in Peninsular Malaysia
Farooq, H., Monowar, T., Latt, S. S., Chinni, S. V., Zainol, N. H., & Sabesan, G. S. (2022) · Advanced Biomedical Research · doi:10.4103/abr.abr_3_22 · Cited by 11
“There are around 154 species in this genus,[1,2] out of which more than 30 species of Candida have been reported to cause infections.”
BackgroundAntifungal Resistance and Genotyping of Clinical Candida parapsilosis Complex in Japan
Khalifa, H. O., Watanabe, A., & Kamei, K. (2023) · Journal of Fungi · doi:10.3390/jof10010004 · Cited by 10
“…to the statewide data reported by Pfaller et al. that suggest C. parapsilosis , a member of the NAC species, is responsible for the majority of invasive candidiasis cases in children (of nine years old) and neonates in North America [20], only 17% of the patients in this study were children.”
Mori, T., Yoshida, M., Hazekawa, M., Ishibashi, D., Hatanaka, Y., Kakehashi, R., Nakagawa, M., Nagao, T., Yoshii, M., Kojima, H., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222112056 · Cited by 10
“antimicrobial activity against Candida albicans [17], which is the most common species causing fungal infections [18,19].”
BackgroundArgüelles, A., Sánchez-Fresneda, R., Guirao-Abad, J. P., Lozano, J. A., Solano, F., & Argüelles, J. C. (2023) · Journal of Fungi · doi:10.3390/jof9040442 · Cited by 10
A 12-year study of fungal infections in Rio Grande do Sul, Southern Brazil
Fay, V. D. S., Gregianini, T. S., da Veiga, A. B. G., Gonçalves, S. M. B., Rodrigues, D. M. G., & Bonamigo, R. R. (2019) · Revista Iberoamericana de Micología · doi:10.1016/j.riam.2018.10.006 · Cited by 12
Rauseo, A. M., Olsen, M. A. A., Stwalley, D. L., Mazi, P. B., Larson, L., Powderly, W. G., & Spec, A. (2022) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofac447 · Cited by 10
“Infections due to fluc-R non-albicans species such as C krusei have a higher propensity to emerge in these settings where prior azole exposure is common, as in BMT/SCT recipients due to long-term prophylaxis [6, 14].”
Ahamad, I., & Fatma, T. (2025) · BioMetals · doi:10.1007/s10534-025-00680-y · Cited by 9
“It might be more prone to this strain of infection compared to the Candida species because it has a remarkable survival rate in immune-compro-mised people (Pfaller et al. 2014).”
Muñoz-Megías, M. L., Sánchez-Fresneda, R., Solano, F., Maicas, S., Martinez‐Esparza, M., & Argüelles, J. C. (2023) · Current Genetics · doi:10.1007/s00294-023-01269-z · Cited by 9
“) and the rising identification in both community and hospitality epidemic outbreaks of fungal species traditionally considered as innocuous (Pfaller and Diekema 2010; Pfaller et al. 2014; Brown et al. 2012; Kainz et al. 2020) conveys additional complications for clinical antifungal chemotherapy, already limited by th…”
BackgroundGautam, S., Sharma, G., Singla, S. K., & Garg, S. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.835421 · Cited by 10
León-Borrás, R. D., DelPilar-Morales, E., Rivera-Pérez, N., Pallens-Feliciano, M., Tírado-Gómez, M., González‐Sepúlveda, L., & Bertrán‐Pasarell, J. (2017) · PubMed · Cited by 11
Carveoylphenols and Their Antifungal Potential against Pathogenic Yeasts
Montenegro, I., Mellado, M., Russo, A., Said, B., Besoain, X. A., Godoy, P., Werner, E., Caro, N., & Madrid, A. (2019) · Antibiotics · doi:10.3390/antibiotics8040185 · Cited by 10
Raj, K., Paul, D., Rishi, P., Shukla, G., Dhotre, D. P., & YogeshSouche (2024) · BMC Microbiology · doi:10.1186/s12866-024-03274-9 · Cited by 8
“Individuals suffering with diabetes, immune deficiencies, hematologic malignancies as well those using indwelling medical devices, receiving parenteral nutrition or undergoing prior surgeries due to other morbidities are most susceptible to candidemia and IC [4–6].”
BackgroundFallah, F., Karimi, A., Azimi, L., Ghandchi, G., Gholinejad, Z., Abdollahi, N., Oskooie, N. A., Khodaei, H., Armin, S., Behzad, A., et al. (2024) · BMC Pediatrics · doi:10.1186/s12887-024-05146-7 · Cited by 8
“Among yeasts, Candida albicans and non-albicans species also play an important role in HABSIs in children [4, 5].”
BackgroundArslan, F., Çaşkurlu, H., Sarı, S., Dal, H. C., Turan, S., Şengel, B. E., Gül, F., Yeşilbağ, Z., Eren, G. A., Temel, Ş., et al. (2018) · Medical Mycology · doi:10.1093/mmy/myy127 · Cited by 8
Bazuhair, M. A., Alsieni, M., Abdullah, H., Mokhtar, J. A., Attallah, D. M., Abujamel, T. S., Alkuwaity, K. K., Niyazi, H. A., Niyazi, H. A., AbdulMajed, H., et al. (2024) · Infection and Drug Resistance · doi:10.2147/idr.s464287 · Cited by 9
Uncommon cause of fungemia in a patient with renal cell cancer
Mishra, R., Kelly, P., Toolsie, O., Ayyadurai, P., & Adrish, M. (2017) · Medicine · doi:10.1097/md.0000000000008510 · Cited by 10
“Patients with solid tumors and those undergoing surgical procedures during hospitalization are at greatest risk of developing this infection.([3]) In immunocompromised patients, the infection often presents as a breakthrough fungemia.”
BackgroundInfluentialBenchouaia, M., Ripoche, H., Sissoko, M., Thiébaut, A., Merhej, J., Delaveau, T., Fasseu, L., Benaissa, S., Lorieux, G., Jourdren, L., et al. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.02689 · Cited by 9
“As mentioned above, selenite triggers several stress responses (iron starvation, oxidative stress response, DNA damage. . .) (Pinson et al., 2000; Salin et al., 2008; Perez-Sampietro et al., 2016) and therefore the ROs identified from the selenite comparative transcriptomics data may actually…”
BackgroundTranscriptional Response of Candida auris to the Mrr1 Inducers Methylglyoxal and Benomyl
Biermann, A. R., & Hogan, D. A. (2022) · mSphere · doi:10.1128/msphere.00124-22 · Cited by 9
Yeast Infections in Solid Organ Transplantation
Taimur, S. (2018) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2018.04.005 · Cited by 9
The Anti-Candida albicans Agent 4-AN Inhibits Multiple Protein Kinases
Masłyk, M., Janeczko, M., Martyna, A., Czernik, S., Tokarska-Rodak, M., Chwedczuk, M., Josselin, B., Ruchaud, S., Bach, S., Demchuk, O. M., et al. (2019) · Molecules · doi:10.3390/molecules24010153 · Cited by 8
“Candida species cause a majority of fungal infections and significantly contribute to morbidity and mortality worldwide, which makes them a serious threat to public health [1].”
BackgroundCaspofungin binding to iron compromises its antifungal efficacy against Candida albicans
Pedras, A., Malta-Luís, C., Lima, L. M. P., Mil‐Homens, D., Amaral, C., Duarte, A. G., Antunes, W., Gaspar‐Cordeiro, A., Louro, R. O., Lamosa, P., et al. (2025) · Communications Biology · doi:10.1038/s42003-025-08834-x · Cited by 7
Satała, D., Karkowska‐Kuleta, J., Braś, G., Rąpała‐Kozik, M., & Kozik, A. (2023) · Yeast · doi:10.1002/yea.3847 · Cited by 7
“2023;40:377–389. wileyonlinelibrary.com/journal/yea © 2023 John Wiley & Sons Ltd. | 377 Alliance registry that involved 23 medical centers in the United States and two in Canada (Pfaller et al., 2014) and the SENTRY program of 135 medical centers in 39 nations (Pfaller et al., 2019) indicated that although the highest…”
BackgroundBalandis, B., Kavaliauskas, P., Grybaitė, B., Petraitis, V., Petraitienė, R., Naing, E., Garcia, A. J., Grigalevičiūtė, R., & Mickevičius, V. (2023) · Microorganisms · doi:10.3390/microorganisms11040935 · Cited by 7
“The MIC of compounds 2–22a–c, as well as clinically approved antifungal drugs was determined by CLSI recommendations that were described in document M27-A3 [36,37].”
MethodElhoufi, A. M., Ahmadi, A., Asnaashari, A. M. H., Davarpanah, M. A., Bidgoli, B. F., Moghaddam, O. M., Torabi-Nami, M., Abbasi, S., El-Sobky, M., Ghaziani, A., et al. (2014) · World Journal of Critical Care Medicine · doi:10.5492/wjccm.v3.i4.102 · Cited by 7
“The current state of our local epidemiologic insights on IFIs are in line with those of international reports [19,20,35-37] .”
Louis, B., Waikhom, S. D., & Atadja, P. W. (2016) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.2016.1147953 · Cited by 7
Gln3 is a main regulator of nitrogen assimilation in Candida glabrata
Santos, F. J. P.-D. L., & Riego‐Ruiz, L. R. (2016) · Microbiology · doi:10.1099/mic.0.000312 · Cited by 7
Jakab, Á., Emri, T., Csillag, K., Szabó, A., Nagy, F., Baranyai, E., Sajtos, Z., Geczi, D. A., Antal, K., Kovács, R., et al. (2021) · Journal of Fungi · doi:10.3390/jof7070540 · Cited by 8
“However, increased susceptibility to superficial and invasive Candida infections has been reported in these BM-based therapies [1,3].”
BackgroundInhibition of morphological transition and hyphae extension in Candida spp. by occidiofungin
Kumpakha, R., & Gordon, D. M. (2021) · Journal of Applied Microbiology · doi:10.1111/jam.15425 · Cited by 7
“…albicans is the most common cause of candidiasis, however recent studies have shown that infections caused by non- albicans Candida species such as C. tropicalis have increased significantly over the years (Guinea, 2014; Jacobsen et al., 2012; Pfaller et al., 2014; Wisplinghoff et al., 2014).”
Asadzadeh, M., Ahmad, S., Al‐Sweih, N., & Khan, Z. (2023) · Frontiers in Public Health · doi:10.3389/fpubh.2023.1242622 · Cited by 7
“(4) The clinical details of patients, disease severity and outcome were not available.”
BackgroundLeite, D. P. (2023) · Virology & Immunology Journal · doi:10.23880/vij-16000331 · Cited by 10
Jospe‐Kaufman, M., Ben‐Zeev, E., Mottola, A., Dukhovny, A., Berman, J. G., Carmeli, S., & Fridman, M. (2023) · Angewandte Chemie · doi:10.1002/ange.202314728 · Cited by 7
Pech-Puch, D., Grilo, D., Calva-Pérez, S. E., Pedras, A., Villegas‐Hernández, H., Guillén-Hernández, S., Díaz-Gamboa, R. E., Forero, A. M., Rodríguez, J., Lenis-Rojas, O. A., et al. (2023) · Molecules · doi:10.3390/molecules28020606 · Cited by 6
“Candida albicans is the most frequent causative agent of nosocomial invasive fungal infections [5], followed by Candida glabrata and Candida parapsilosis [8].”
BackgroundAsadzadeh, M., Alobaid, K., Ahmad, S., & Mazloum, S. (2023) · Journal of Fungi · doi:10.3390/jof9080784 · Cited by 6
Microevolution of Candida glabrata (Nakaseomyces glabrata) during an infection
López-Marmolejo, A. L., Hernández-Chávez, M. J., Gutiérrez‐Escobedo, G., Herrera-Basurto, M. S., Mora-Montes, H. M., Peñas, A. D. L., & Castaño, I. (2024) · Fungal Genetics and Biology · doi:10.1016/j.fgb.2024.103891 · Cited by 7
Bavaro, D. F., Diella, L., Angelis, A. D., Vanoni, M., Belati, A., Santis, L. D., Bussini, L., Montemurro, L., Papale, R., Ronga, L., et al. (2025) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2025.108046 · Cited by 6
Fluconazole-induced changes in azole resistance and biofilm production in Candida glabrata in vitro
Xia, C., Liu, R., Zhang, S., Shen, J., & Wang, Z. (2025) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2025.116683 · Cited by 7
Efunshile, A., Oduyebo, O. O., Osuagwu, C. S., & Koenig, B. F. (2016) · African Journal of Clinical and Experimental Microbiology · doi:10.4314/ajcem.v17i3.5 · Cited by 7
Candida Infections in Solid Organ Transplantation
Barros, N., & Mansour, M. K. (2021) · Springer eBooks · doi:10.1007/978-3-030-25869-6_43 · Cited by 7
Identification of novel inhibitors against Med15a KIX domain of Candida glabrata
Waseem, M., Das, S., Mondal, D., Jain, M., Thakur, J. K., & Subbarao, N. (2023) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2023.126720 · Cited by 6
Genetically Compromising Phospholipid Metabolism Limits Candida albicans’ Virulence
Wong, D., Plumb, J., Talab, H., Kurdi, M., Pokhrel, K., & Oelkers, P. M. (2019) · Mycopathologia · doi:10.1007/s11046-019-00320-3 · Cited by 6
Vahedi‐Shahandashti, R., Moroder, E., & Lass‐Flörl, C. (2025) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00241-25 · Cited by 5
Sánchez-Fresneda, R., Muñoz-Megías, M. L., Yagüe, G., Solano, F., Maicas, S., & Argüelles, J. C. (2022) · Journal of Fungi · doi:10.3390/jof8040371 · Cited by 5
“Although Candida albicans remains the most prevalent species of Candida responsible for both superficial and invasive candidiasis, which mainly affects the immunodebilitated population [1–3], another group of opportunistic yeasts belonging to the genus Candida and referred to as “non-albicans” has emerged in recent ye…”
BackgroundIra-Bonouman, A., Krasteva, D., Kouadjo, F. K., Roger, F., Bellet, V., Koffi, D., Pottier, C., Touré, O. A., Drakulovski, P., Djaman, A. J., et al. (2023) · Journal de Mycologie Médicale · doi:10.1016/j.mycmed.2023.101410 · Cited by 7
Antifungal therapies in murine infections by Candida kefyr
Sanchis, M., Martín‐Vicente, A., Capilla, J., & Guarro, J. (2016) · Mycoses · doi:10.1111/myc.12468 · Cited by 8
Yang, X., Liu, M., Yu, X., Wang, Z., & Xu, Y. X. (2022) · Infection and Drug Resistance · doi:10.2147/idr.s383846 · Cited by 5
Seyedmousavi, S., İlkit, M., Durdu, M., Ergin, Ç., Polat, S. H., Melchers, W. J. G., & Verweij, P. E. (2015) · Türk Mikrobiyoloji Cemiyeti Dergisi · doi:10.5222/tmcd.2015.001 · Cited by 5
Transcription Profiles Associated with Inducible Adhesion in Candida parapsilosis
Bliss, J. M., Tollefson, G. A., Cuevas, A., Longley, S. J., Neale, M. N., Uzun, A., & Shaw, S. K. (2021) · mSphere · doi:10.1128/msphere.01071-20 · Cited by 5
“auris are emerging as significant causes of systemic infection, especially in the setting of immune compromise (2).”
BackgroundRanjbar‐Mobarake, M., Nowroozi, J., Badiee, P., Mostafavi, S. N., & Mohammadi, R. (2021) · Journal of Research in Medical Sciences · doi:10.4103/jrms.jrms_156_21 · Cited by 5
Takuma, A., Inoue, E., Momo, K., Kuroki, T., Uchikura, T., Watanabe, T., & Sasaki, T. (2022) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2022.10.011 · Cited by 5
Klesiewicz, K., Mrowiec, P., Kania, K., Skiba‐Kurek, I., Białecka, J., Namysł, M., & Małek, M. (2023) · Polish Journal of Microbiology · doi:10.33073/pjm-2023-011 · Cited by 5
“More than 40 species of the Candida genus are capable of causing infection (Pfaller et al. 2014), but Candida albicans remain a significant cause of VVC (Sobel and Sobel 2018).”
BackgroundPalande, V., Rajeev, M., Sonavale, R. M., Makashir, M., Modak, M. S., Kapse, N. G., Dhakephalkar, P. K., & Ranjekar, P. K. (2015) · Cited by 6
Devi, L. S., Madhuri, Sharma, M., & Sardar, M. (2025) · Cureus · doi:10.7759/cureus.94311 · Cited by 4
Song, Y., & Li, R. (2024) · Elsevier eBooks · doi:10.1016/b978-0-12-818619-0.00083-6 · Cited by 4
Leal, V. L., Machado, G. D. R. M., Kliemann, M., Teixeira, M. L., Schneider, R. D. C. D. S., da Silva, C. D. M., & Fuentefría, A. M. (2021) · Scientific Electronic Archives · doi:10.36560/14620211347 · Cited by 4
Aonofriesei, F. (2023) · Microorganisms · doi:10.3390/microorganisms12010051 · Cited by 4
Bondaryk, M., Grabowska‐Jadach, I., Ochal, Z., Sygitowicz, G., & Staniszewska, M. (2016) · Chemical Papers · doi:10.1515/chempap-2016-0072 · Cited by 5
“Candida spp. is the leading opportunistic fungal pathogen and it can be found on the mucosal surfaces of the human body (Pfaller et al., 2014; Richardson & Moyes, 2015).”
BackgroundEsophageal candidiasis in patients from a specialty hospital
Méndez‐Tovar, L. J., Rodríguez-Sánchez, J. F., Manzano–Gayosso, P., Hernández, F. H., Blancas-Valencia, J. M., & Silva-González, I. (2019) · PubMed · Cited by 4
Veselov, A. V., Vasilyeva, N. V., Богомолова, Т. С., Рудольфовна, Р. Е., Kutsevalova, O. Y., Нижегородцева, И. А., Петрова, Л. В., Shmidt, N. V., Moskvitina, E. N., Витальевна, С. М., et al. (2018) · Clinical Microbiology and Antimicrobial Chemotherapy · doi:10.36488/cmac.2018.1.49-54 · Cited by 4
Lass‐Flörl, C., Krause, R., Willinger, B., Starzengrüber, P., Decristoforo, P., Neururer, S. B., Kreidl, P., & Aigner, M. (2020) · Journal of Fungi · doi:10.3390/jof6020076 · Cited by 4
Metadata
- Authors
- Pfaller, M. A., Andes, D. R., Diekema, D. J., Horn, D. L., Reboli, A. C., Rotstein, C., Franks, B., & Azie, N. E.
- Affiliations
- University of Iowa (US)
- University of Wisconsin–Madison (US)
- Cooper Medical School of Rowan University (US)
- University of Toronto (CA)
- Astellas Pharma (United States) (US)
- Corresponding author
- Pfaller, Michael A.
- ORCID
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2014-07-03
- Volume
- 9
- Issue
- 7
- Pages
- e101510
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC4081561
- OpenAlex
- W2053909542
- Cited by
- 396
- References
- 69
- Citations by year
- 2026: 5 · 2025: 14 · 2024: 21 · 2023: 33 · 2022: 34 · 2021: 33 · 2020: 47 · 2019: 48 · 2018: 41 · 2017: 43 · 2016: 39 · 2015: 34 · 2014: 4
- FWCI
- 28.12
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Pfizer
- Massachusetts General Hospital
- University of Nebraska Medical Center
- University of Miami
- University of Pennsylvania
- Emory University
- Bunning Food Allergy Institute, Ann and Robert H. Lurie Children's Hospital of Chicago
- University of Minnesota
- University of Washington
- Johns Hopkins University
- University of Pittsburgh
- Hamilton Health Sciences
- Thomas Jefferson University
- University of Arkansas for Medical Sciences
- City of Hope
- Astellas Pharma
- University of Texas MD Anderson Cancer Center
- Medical Center, University of Pittsburgh
- National Institute of Allergy and Infectious Diseases
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
- Life Sciences › Immunology and Microbiology › Microbiology › Yeasts and Rust Fungi Studies
- Keywords
- invasive candidiasis, non-albicans Candida, Candida glabrata, Candida parapsilosis, Candida tropicalis, Candida krusei, Candida lusitaniae, Candida dubliniensis, Candida guilliermondii, Candida species distribution, antifungal therapy, fluconazole, echinocandins, 90-day survival, solid organ transplant recipients, solid tumors
- MeSH terms
- Adolescent, Adult, Aged, Aged, 80 and over, Antifungal Agents, Candida, Child, Child, Preschool, Drug Therapy, Combination, Female, Humans, Infant, Male, Middle Aged, Prospective Studies, Registries, Fluconazole, Prevalence, Survival Rate, Treatment Outcome, Echinocandins, Young Adult, Candidiasis, Invasive
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
